Breaking Finance News

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $3.00, Orexigen Therapeutics, Inc. (NASDAQ:OREX) traded -0.34% lower on the day. With the last stock price down -28.31% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. OREX has recorded a 50-day average of $3.53 and a two hundred day average of $4.14. Trade Volume was down over the average, with 120,004 shares of OREX changing hands under the typical 174,869

Zacks Investment Research has upgraded Orexigen Therapeutics, Inc. (NASDAQ:OREX) to Hold in a statement released on 10/12/2016.

Recent Performance Chart

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Orexigen Therapeutics, Inc. has with a one year low of $2.88 and a one year high of $34.40 and has a market capitalization of $0.

A total of 6 brokerages have issued a ratings update on Orexigen Therapeutics, Inc.. One brokerage rating the company a strong buy, four brokerages rating the company a buy, two brokerages rating the company a hold, one brokerage rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $1.67.

General Company Details For Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *